Aspirin for prevention of preeclampsia and fetal growth restriction. (3rd February 2020)

• Record Type: Journal Article
• Authors: Loussert, Lola; Vidal, Fabien; Parant, Olivier; Hamdi, Safouane M.; Vayssiere, Christophe; Guerby, Paul
• Is Part Of: Prenatal diagnosis. Volume 40:Number 5(2020)
• Page Start: 519
• Page End: 527
• Publication Date: 2020-02-03
• Subjects: Prenatal diagnosis -- Periodicals; Fetus -- Diseases -- Diagnosis -- Periodicals; Electronic journals; 618.32075
• DOI: 10.1002/pd.5645
• Languages: English
• ISSNs: 0197-3851

Abstract

Abstract: For the past decades, growing attention has been given to aspirin use during pregnancy. It favors placentation by its proangiogenic, antithrombotic, and anti‐inflammatory effects. Therefore, low doses of aspirin are prescribed in the prevention of placenta‐mediated complications, mainly preeclampsia and fetal growth restriction. However, questions regarding its clinical application are still debated. Aspirin is effective in preventing preeclampsia in a high‐risk population. Most guidelines recommend that risk stratification should rely on medical history. Nevertheless, screening performances dramatically improve if biochemical and biophysical markers are included. Concerning the appropriate timing and dose, latest studies suggest aspirin should be started before 16 weeks of pregnancy and at a daily dose of 100 mg or more. Further studies are needed to improve the identification of patients likely to benefit from prophylactic aspirin. Besides, the role of aspirin in the prevention of fetal growth restriction is still questioned.